{"id":625942,"date":"2022-11-16T18:46:02","date_gmt":"2022-11-16T18:46:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=625942"},"modified":"2022-11-16T18:46:02","modified_gmt":"2022-11-16T18:46:02","slug":"focal-segmental-glomerulosclerosis-market-analysis-of-epidemiology-pipeline-therapies-and-key-companies-working-in-the-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-market-analysis-of-epidemiology-pipeline-therapies-and-key-companies-working-in-the-market_625942.html","title":{"rendered":"Focal Segmental Glomerulosclerosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Focal Segmental Glomerulosclerosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Focal Segmental Glomerulosclerosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Focal Segmental Glomerulosclerosis (FSGS) \u2013 Market Insights, Epidemiology, and Market Forecast \u2013 2032\u2019 report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Focal Segmental Glomerulosclerosis (FSGS) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &lsquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=satPR&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Focal Segmental Glomerulosclerosis (FSGS) &ndash; Market Insights, Epidemiology, and Market Forecast &ndash; 2032&rsquo; <\/a><\/strong>report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Focal Segmental Glomerulosclerosis (FSGS) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;The Focal Segmental Glomerulosclerosis (FSGS) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Focal Segmental Glomerulosclerosis (FSGS) market size from 2019 to 2032, segmented by seven major markets. The report also covers the current Focal Segmental Glomerulosclerosis (FSGS) treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key facts of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=satPR&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Focal Segmental Glomerulosclerosis Market Report:<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A US population-based study by Sim et al. (2016) examined 2,501 adult kidney biopsies between 2000 and 2011. As per the study, FSGS was the most commonly diagnosed glomerulonephropathy (38.9% of biopsies) across all races and ethnic groups, with an average incidence rate for FSGS being 2.7 patients per 100,000.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the Nephcure (n.d.), around 40,000 people are living with FSGS in the United States. In addition, more than 5,400 people are diagnosed with FSGS every year.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key benefits of the report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report covers the descriptive overview of Focal Segmental Glomerulosclerosis (FSGS), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Comprehensive insight is provided into the Focal Segmental Glomerulosclerosis (FSGS) epidemiology and treatment in the 7MM<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Additionally, an all-inclusive account of both the current and emerging therapies for Focal Segmental Glomerulosclerosis (FSGS) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A detailed review of the Focal Segmental Glomerulosclerosis (FSGS) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides an edge while developing business strategies by understanding trends shaping and driving the global Focal Segmental Glomerulosclerosis (FSGS) market<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Got queries? Click here to learn more about<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=satPR&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Focal Segmental Glomerulosclerosis&nbsp; Market Insights&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/828be353069ad4e5172a7e70c06b46bf.jpg\" alt=\"\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman&rsquo;s capsule.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">It is focal in that only some glomeruli are affected and segmental where only a portion of the affected glomerulus is sclerosed. It typically presents with nephrotic syndrome with characterized proteinuria and obliteration or failure of glomerular capillary loops by increased extracellular matrix in glomeruli capillary tufts.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">However, the capillary injury does not occupy the entire glomerulus.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">FSGS treatment goal is to control or eliminate proteinuria and preserve kidney function in children with FSGS. Currently, there are no FDA-approved therapies for FSGS. The pharmacologic treatment has a success rate of 20&ndash;40% with the present agents available, including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, corticosteroids, calcineurin inhibitors, mycophenolate mofetil, and rituximab. Moreover, dialysis and kidney transplants become the next treatment options when medications fail.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Renin-aldosterone system blockade medications that target the renin-angiotensin-aldosterone system to reduce proteinuria and prevent hypertension are the standard of care for patients with FSGS.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis&nbsp; Epidemiological Insights<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The total 7MM diagnosed prevalent cases of focal segmental glomerulosclerosis (FSGS) in 2021 were more than 200,000, out of which the highest prevalent cases of this disease were in the United States. In EU5 countries, Germany accounted for over 23,000 cases in 2021.&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Japan had close to 35,000 cases in 2021, which accounted for approximately YY% of the total 7MM diagnosed prevalent cases of FSGS.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per the estimates by DelveInsight, the total diagnosed prevalent population will reach more than 300,000 cases by 2032 for the study period of 2019&ndash;2032.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis Epidemiological Segmentation&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total &nbsp;Focal Segmental Glomerulosclerosis diagnosed cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total&nbsp; Focal Segmental Glomerulosclerosis age-specific cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Focal Segmental Glomerulosclerosis type-specific cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis&nbsp; Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Focal Segmental Glomerulosclerosis (FSGS) market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Focal Segmental Glomerulosclerosis (FSGS) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">This segment gives a thorough detail of the Focal Segmental Glomerulosclerosis (FSGS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">According to DelveInsight, the Focal Segmental Glomerulosclerosis (FSGS) market in the 7MM is expected to change in 2019&ndash;2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Learn more by requesting for sample @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-market\">F<strong>ocal Segmental Glomerulosclerosis Market Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Travere Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dimerix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Goldfinch Bio<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And many others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis Key Therapies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sparsentan<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DMX-200<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GFB-887<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And many others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of Focal Segmental Glomerulosclerosis&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidemiology and patient population&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Focal Segmental Glomerulosclerosis Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Focal Segmental Glomerulosclerosis&nbsp; Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Focal Segmental Glomerulosclerosis&nbsp; Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disclaimer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\">Click here to read more about<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/campylobacter-infections-market?utm_source=satPR&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Focal Segmental Glomerulosclerosis&nbsp; Market Insights<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=focal-segmental-glomerulosclerosis-market-analysis-of-epidemiology-pipeline-therapies-and-key-companies-working-in-the-market\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91 9568243403<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=focal-segmental-glomerulosclerosis-market-analysis-of-epidemiology-pipeline-therapies-and-key-companies-working-in-the-market\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Focal Segmental Glomerulosclerosis (FSGS) \u2013 Market Insights, Epidemiology, and Market Forecast \u2013 2032\u2019 report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Focal Segmental Glomerulosclerosis (FSGS) &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-market-analysis-of-epidemiology-pipeline-therapies-and-key-companies-working-in-the-market_625942.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-625942","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/625942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=625942"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/625942\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=625942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=625942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=625942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}